Intervention Review

5-alpha-reductase inhibitors for prostate cancer prevention

  1. Timothy J Wilt1,*,
  2. Roderick MacDonald1,
  3. Karen Hagerty2,
  4. Paul Schellhammer3,
  5. Barnett S Kramer4

Editorial Group: Cochrane Urology Group

Published Online: 23 APR 2008

Assessed as up-to-date: 14 FEB 2008

DOI: 10.1002/14651858.CD007091

How to Cite

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. 5-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD007091. DOI: 10.1002/14651858.CD007091.

Author Information

  1. 1

    VAMC, General Internal Medicine (111-0), Minneapolis, Minnesota, USA

  2. 2

    American Society of Clinical Oncology, Clinical Affairs, Alexandria, Virginia, USA

  3. 3

    Eastern Virginia Medical School, Deoartment of Urology, Norfolk, Virginia, USA

  4. 4

    National Institutes of Health, Bethesda, Maryland, USA

*Timothy J Wilt, General Internal Medicine (111-0), VAMC, One Veterans Drive, Minneapolis, Minnesota, 55417, USA.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 APR 2008


Cited in:


This article has been cited by:

  1. 1
    Ganna Chornokur, Nagi B. Kumar, Prostate cancer chemoprevention in men of African descent: current state of the art and opportunities for future research, Cancer Causes & Control, 2013, 24, 8, 1465


  2. 2
    Nina Holzapfel, Boris Holzapfel, Simon Champ, Jesper Feldthusen, Judith Clements, Dietmar Hutmacher, The Potential Role of Lycopene for the Prevention and Therapy of Prostate Cancer: From Molecular Mechanisms to Clinical Evidence, International Journal of Molecular Sciences, 2013, 14, 7, 14620


  3. 3
    Dragan Ilic, Marie Misso, Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review, Maturitas, 2012, 72, 4, 269


  4. 4
    David Skillinge, Robert Langan, Michael Krafczyk, Martha McGarey, Benign prostate hyperplasia: a clinical review, Osteopathic Family Physician, 2011, 3, 5, 182


  5. 5
    Timothy J. Wilt, Roderick MacDonald, Karen Hagerty, Paul Schellhammer, James Tacklind, Mark R. Somerfield, Barnett S. Kramer, 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review, BJU International, 2010, 106, 10
  6. 6
    Andrew J. Stephenson, Robert Abouassaly, Eric A. Klein, Chemoprevention of Prostate Cancer, Urologic Clinics of North America, 2010, 37, 1, 11


  7. 7
    Larissa A. Korde, Shahinaz M. Gadalla, Cancer Risk Assessment for the Primary Care Physician, Primary Care: Clinics in Office Practice, 2009, 36, 3, 471


  8. 8
    John M. Fitzpatrick, Claude Schulman, Alexandre R. Zlotta, Fritz H. Schröder, Prostate cancer: a serious disease suitable for prevention, BJU International, 2009, 103, 7
  9. 9
    Patrick C. Walsh, Urological Oncology: Prostate Cancer, The Journal of Urology, 2009, 182, 1, 145


  10. 10
    Barnett S. Kramer, Karen L. Hagerty, Stewart Justman, Mark R. Somerfield, Peter C. Albertsen, William J. Blot, H. Ballentine Carter, Joseph P. Costantino, Jonathan I. Epstein, Paul A. Godley, Russell P. Harris, Timothy J. Wilt, Janet Wittes, Robin Zon, Paul Schellhammer, Use of 5α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline, The Journal of Urology, 2009, 181, 4, 1642


  11. 11
    Donald Poirier, New cancer drugs targeting the biosynthesis of estrogens and androgens, Drug Development Research, 2008, 69, 6
  12. 12
    Kristian M Forbes, Dragan Ilic, Craig Hassed, Lycopene for the prevention of prostate cancer, The Cochrane Library,
  13. 13
    Dragan Ilic, Kristian M Forbes, Craig Hassed, Lycopene for the prevention of prostate cancer, The Cochrane Library,
  14. 14
    Dragan Ilic, Molly M Neuberger, Mia Djulbegovic, Philipp Dahm, Screening for prostate cancer, The Cochrane Library,